Skip to content

Study · Randomized controlled trial · n = 104 · 2021

3 results

Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.

Snitker S, Andersen A, Berg B, van Marle S, Sparre T

Diabetes, obesity & metabolism18 Mar 2021Cited by 6 (Europe PMC)

PMID33591618 (opens in a new tab)PMCIDPMC8251561 (opens in a new tab)DOI10.1111/dom.14349 (opens in a new tab)PepBankPUB-33591618
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy subjects, injection-site pain intensity was lower with the semaglutide 0.25 mg starting dose than with dulaglutide 0.75 mg.

    In plain wordsIn healthy people, the semaglutide starting-dose injection hurt less than the dulaglutide injection.

    Peptide
    Semaglutide
    Outcome
    DecreaseInjection-site pain intensity (VAS)
    Study

    n = 104

    Comparator
    Dulaglutide 0.75 mg
    Analysis
    Primary
    Outcome group
    Pain · Pharmacology
    Studied dose
    0.25 mg · injectionAs given in this study (human).

    Measurements

    VAS pain intensity
    5.6 mm
    semaglutide 0.25 mg
    VAS pain intensity
    11.5 mm
    dulaglutide 0.75 mg
    Estimated treatment difference
    5.9 mm
    dulaglutide minus semaglutide

    Source sentences

    Summary
    The point estimate of the VAS score for injection-site pain intensity was 11.5 mm with dulaglutide versus 5.6 mm with semaglutide; mean (95% confidence interval) estimated treatment difference 5.9 (3.6; 8.2) mm; p < .0001.
    2 context sentences
    Summary · context
    The primary endpoint was intensity of injection-site pain, measured using a visual analogue scale (VAS; 0 mm = no pain, 100 mm = unbearable pain).
    Summary · context
    Healthy subjects (aged 18-75 years; body mass index ≥ 25 kg/m2 ; n = 104) were randomized 1:1, using a pregenerated list, to semaglutide 0.25 mg as the first injection and dulaglutide 0.75 mg as the second injection or vice versa; each was administered using their proprietary pen-injector…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy subjects, other endpoints corroborated a less painful injection experience with semaglutide than with dulaglutide.

    In plain wordsIn healthy people, other pain measures also showed that semaglutide injections hurt less than dulaglutide injections.

    Peptide
    Semaglutide
    Outcome
    DecreaseOther injection-site pain endpoints (exploratory)
    Study

    n = 104

    Comparator
    Dulaglutide 0.75 mg
    Analysis
    Exploratory
    Outcome group
    Pain · Pharmacology
    Studied dose
    0.25 mg · injectionAs given in this study (human).

    Source sentences

    Summary
    Other endpoints corroborated a less painful injection experience with semaglutide versus dulaglutide.
    2 context sentences
    Summary · context
    Exploratory endpoints included intensity category, duration and quality of injection-site pain, and comparative assessment of injection-site pain with the two injections.
    Summary · context
    Healthy subjects (aged 18-75 years; body mass index ≥ 25 kg/m2 ; n = 104) were randomized 1:1, using a pregenerated list, to semaglutide 0.25 mg as the first injection and dulaglutide 0.75 mg as the second injection or vice versa; each was administered using their proprietary pen-injector…
  3. 03HumanRandomized controlled trialSafety outcome

    In healthy subjects, safety of the semaglutide and dulaglutide starting doses was consistent with reported data for the drugs.

    In plain wordsIn healthy people, the safety of both injections matched what is already reported for the drugs.

    Peptide
    Semaglutide
    Outcome
    No significant changeSafety
    Study

    n = 104

    Comparator
    Dulaglutide 0.75 mg
    Outcome group
    Adverse events · Pharmacology
    Studied dose
    0.25 mg · injectionAs given in this study (human).

    Source sentences

    Summary
    Safety was consistent with reported data for the drugs.
    1 context sentence
    Summary · context
    Healthy subjects (aged 18-75 years; body mass index ≥ 25 kg/m2 ; n = 104) were randomized 1:1, using a pregenerated list, to semaglutide 0.25 mg as the first injection and dulaglutide 0.75 mg as the second injection or vice versa; each was administered using their proprietary pen-injector…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT04189848

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

Novo Nordisk A/Sn = 1043 Dec 2019 to 27 Feb 2020

Healthy Volunteers · Diabetes Mellitus, Type 2 · Overweight · Obesity

Trial pageClinicalTrials.govUpdated 7 Nov 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 9Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    11 Oct 2026, 00:50 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.